Hebei Senlang Biotechnology
Senlang’s CD7-targeted lentiviral in vivo CAR-T portfolio includes a BCMA/GPRC5D candidate in Phase 1 dose escalation for relapsed/refractory myeloma. Partner Tempest disclosed an exclusive option in September 2026; an option is not an exercised license or acquisition.
Corporate information
- Company entity
- Hebei Senlang Biotechnology
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- Independent company website not verified
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Senlang’s CD7-targeted lentiviral in vivo CAR-T portfolio includes a BCMA/GPRC5D candidate in Phase 1 dose escalation for relapsed/refractory myeloma. Partner Tempest disclosed an exclusive option in September 2026; an option is not an exercised license or acquisition.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.